ImmunityBio, Inc. presented new patient survey data at ISPOR 2026 showing that many UK adults living with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer place significant value on bladder preservation when weighing treatment options after BCG failure. The study, conducted with Fight Bladder Cancer, examined how patients compare radical cystectomy with bladder-sparing therapies in a disease setting where clinical control, quality of life, age, treatment history, and personal priorities can pull decisions in different directions.

Why ImmunityBio’s patient preference data could matter for NMIBC treatment adoption after BCG failure

The most important signal from ImmunityBio’s ISPOR 2026 presentation is not simply that many patients prefer to preserve the bladder. The deeper point is that non-muscle-invasive bladder cancer decision-making is becoming harder to frame around a single clinical pathway, particularly after BCG stops working. For years, radical cystectomy has represented a definitive treatment option for high-risk patients, but it also carries a life-altering burden. Bladder-sparing therapies, by contrast, promise organ preservation and potentially less disruption, but they must still prove that they can deliver durable disease control in a population where progression risk remains a central concern.

That tension is commercially and clinically important for ImmunityBio because its bladder cancer strategy sits inside a treatment field where patient-centered evidence can influence how clinicians discuss available options, how payers assess value, and how regulators view real-world unmet need. Survey data cannot replace randomized clinical evidence, response durability, or long-term safety outcomes. However, it can help explain why a therapy that delays or avoids cystectomy may carry value beyond conventional response metrics. In NMIBC, the endpoint is not only whether disease recurs or progresses. It is also whether the patient can maintain function, independence, daily routines, and identity after treatment.

The limitation is that preference data can be powerful but also easy to overinterpret. A survey of 86 UK adults provides useful directional insight, especially when supplemented by interviews and focus groups, but it does not automatically predict how patients will choose when facing a real-time treatment crisis, physician recommendation, reimbursement constraints, or a rapidly changing risk profile. Patients may express a preference for bladder preservation in principle while still choosing surgery if they believe cancer control is materially stronger. That is why the ImmunityBio data are best understood as a decision-context study, not as evidence that one treatment pathway is universally preferred.

How bladder preservation is becoming a stronger quality-of-life theme in high-risk bladder cancer

Bladder preservation has become one of the most emotionally charged and clinically complicated themes in NMIBC because it sits between two priorities that are both rational. On one side, patients and clinicians want to reduce the risk of recurrence, progression, metastasis, and death. On the other, patients want to avoid the physical, psychological, sexual, and lifestyle consequences that can follow radical cystectomy. ImmunityBio’s survey data reinforce that patients are not making these decisions as passive recipients of a treatment algorithm. They are weighing survival, hospital burden, urinary function, lifestyle disruption, and personal tolerance for uncertainty.

The finding that patients actively receiving BCG were more likely to favor bladder preservation is especially revealing. These patients may still be psychologically anchored to intravesical or less invasive treatment pathways, making the possibility of organ preservation feel both familiar and desirable. By contrast, patients who had already undergone radical cystectomy were more likely to support repeating that decision, suggesting that lived experience can validate a more aggressive choice once patients have passed through it. This split matters because it shows that “patient preference” is not a fixed category. It changes with treatment history, age, symptom burden, physician trust, and how patients interpret risk.

For developers of bladder-sparing therapies, that creates both opportunity and pressure. The opportunity lies in positioning treatment around real patient priorities, especially for individuals who strongly want to delay or avoid bladder removal. The pressure lies in demonstrating that such therapies do not merely offer emotional reassurance but provide clinically meaningful cancer control. If bladder preservation becomes detached from robust oncologic outcomes, clinicians will remain cautious. In high-risk NMIBC, a bladder-sparing option must compete not only on convenience or tolerability but on the credibility of its durability.

Why clinical effectiveness remains the decisive factor despite patient interest in avoiding cystectomy

One of the more grounded aspects of the ImmunityBio survey is that clinical effectiveness still emerged as the most important factor influencing treatment decisions. That matters because it prevents the data from being read as a simple quality-of-life story. Patients may value bladder preservation, but they are not ignoring recurrence, progression, or life expectancy. Instead, they appear to be asking a more nuanced question: how much clinical certainty must be exchanged for organ preservation, and where does that trade-off become acceptable?

This is the central challenge facing all bladder-sparing approaches in BCG-unresponsive high-risk NMIBC. The disease category is not benign. The phrase non-muscle-invasive can sound less severe to general readers, but high-risk NMIBC after BCG failure can carry a serious risk of progression. Radical cystectomy remains a major reference point because it can remove the diseased organ and reduce future bladder-specific risk, even though the procedure is invasive and life-changing. Any alternative must therefore answer a difficult clinical question, not merely a preference question. Can it maintain disease control long enough, in enough patients, with a safety profile that justifies deferring surgery?

For ImmunityBio, patient preference data may help support the broader argument that therapies in this setting should be assessed through a multidimensional lens. Response rates, complete response durability, progression-free outcomes, adverse events, retreatment needs, and treatment logistics all matter. However, quality of life and patient trade-off tolerance are also part of the value equation. The unresolved question is how strongly such preference data can shape real-world adoption when clinicians remain primarily accountable for oncologic risk. In practice, the strongest commercial case will come from aligning patient preference with durable clinical performance, not from preference alone.

What the UK survey suggests about age, gender, and individualized decision-making in NMIBC

The age-related finding in the survey adds another layer to the treatment debate. Older participants showed a lower preference for radical cystectomy, which is plausible given the physical burden of major surgery, comorbidity considerations, recovery time, and potential impact on independence. In older patients, a bladder-sparing strategy may appear more attractive if it offers disease control without the disruption of a major operation. However, older age can also complicate repeated hospital visits, monitoring intensity, treatment adherence, and management of adverse events.

The gender-related finding also deserves attention. Male participants expressed greater concern about the daily-life impact of radical cystectomy, which points toward the need for more personalized counseling around body image, sexual function, urinary diversion, mobility, work, and social routines. These considerations are often discussed clinically, but they may not always be captured fully in traditional endpoint-driven trial narratives. If patient-reported outcomes become more influential in NMIBC, they could help clinicians better identify which patients are likely to accept frequent monitoring or additional treatments in exchange for avoiding cystectomy.

The risk is that demographic patterns can be misused if they become overly generalized. Older patients are not automatically poor surgical candidates. Younger patients are not automatically willing to accept cystectomy. Men and women may experience lifestyle disruption differently, but individual values remain decisive. The strongest implication from the ImmunityBio data is therefore not that treatment should be segmented mechanically by age or gender. It is that clinicians need more structured conversations to identify what each patient is willing to trade, what risk each patient understands, and how treatment goals may change over time.

Why patient-centered evidence may influence reimbursement and real-world NMIBC treatment pathways

Patient-centered evidence has growing relevance in oncology because health systems are under pressure to evaluate therapies in terms of total value, not just tumor response. In BCG-unresponsive NMIBC, that value may include avoiding or delaying radical cystectomy, preserving daily function, reducing psychological burden, and maintaining quality of life. For a therapy developer such as ImmunityBio, preference data can help frame the unmet need in a way that resonates with clinicians, payers, and policy stakeholders.

This is particularly important in markets where cost-effectiveness, quality-adjusted life years, hospital resource use, and patient-reported outcomes influence access discussions. A bladder-sparing therapy may involve ongoing monitoring, repeated visits, drug acquisition costs, procedure time, and adverse event management. Radical cystectomy, however, also carries surgical cost, hospitalization, complications, rehabilitation, and long-term quality-of-life implications. The economic question is not simply which option costs less at the point of treatment. It is which pathway delivers acceptable cancer control while preserving the greatest overall value for patients and health systems.

The limitation is that preference evidence must be linked to real outcomes before it can significantly change reimbursement behavior. Payers may acknowledge that patients want to avoid cystectomy, but they will still look for durability, safety, comparative context, and predictable resource use. If bladder-sparing approaches require intensive surveillance or frequent retreatment, payers will ask whether the clinical benefit justifies the total pathway cost. Patient preference can strengthen the case, but it cannot carry the case alone.

What clinicians and industry observers are likely to watch next in bladder-sparing NMIBC care

Clinicians tracking NMIBC will likely focus on whether bladder-sparing therapies can continue to show durable benefit in clearly defined patient populations. The field needs clarity on which patients are most suitable for bladder preservation, how long cystectomy can safely be deferred, and what clinical triggers should prompt a move to surgery. These questions are not abstract. A delayed cystectomy can be valuable if disease remains controlled, but it can become risky if progression occurs during an extended period of bladder-sparing treatment.

Industry observers will also watch how patient preference data are incorporated into future trial design, labels, guidelines, and health technology assessments. The more NMIBC studies include patient-reported outcomes, treatment burden measures, and shared decision-making frameworks, the easier it becomes to compare therapies beyond raw response rates. That could benefit companies developing treatments that preserve function while maintaining cancer control. However, it may also raise the evidentiary bar, because developers will need to show that patients not only prefer an approach but also benefit from it in measurable and durable ways.

For ImmunityBio, the ISPOR 2026 survey supports a broader narrative around patient-centered bladder cancer care. It highlights why the BCG-unresponsive NMIBC setting is not merely a clinical niche but a high-stakes decision arena where cancer control and life disruption collide. The data do not eliminate the role of radical cystectomy, nor do they prove that every patient should pursue bladder preservation. What they do show is that the future of NMIBC care is likely to be more individualized, more preference-sensitive, and more demanding for therapy developers that want to compete in this space.

Why ImmunityBio’s ISPOR data point to a more complex commercial story for NMIBC therapies

The commercial takeaway is that bladder-sparing NMIBC therapies are not competing only on science. They are competing on trust. Patients must trust that they are not sacrificing too much cancer control. Clinicians must trust that the evidence supports deferring a definitive surgical option. Payers must trust that the pathway provides value beyond emotional appeal. Regulators must trust that benefits are clinically meaningful and not merely convenient.

That makes ImmunityBio’s patient survey relevant, even though it is not a pivotal efficacy readout. It helps map the emotional and practical terrain into which NMIBC therapies are being launched, prescribed, reimbursed, and monitored. In a treatment setting where patients may be willing to accept more hospital visits to avoid bladder removal, the market opportunity for bladder preservation is real. But it will remain tied to the same hard questions that shape all oncology adoption: how durable is the benefit, how manageable is the risk, and which patients are most likely to gain from the approach?

The most balanced interpretation is that ImmunityBio’s ISPOR 2026 presentation strengthens the case for shared decision-making in BCG-unresponsive high-risk NMIBC. It also reminds the industry that patient preference is not a soft endpoint when treatment choices can permanently alter daily life. At the same time, it keeps the clinical bar intact. Bladder preservation may be a powerful goal, but in high-risk bladder cancer, preservation must be earned through evidence, not assumed through preference.

  ANKTIVA, BCG-unresponsive bladder cancer, bladder preservation, cancer immunotherapy, Fight Bladder Cancer, ImmunityBio, ISPOR 2026, NMIBC, patient preference, radical cystectomy